0001209191-20-007477.txt : 20200207
0001209191-20-007477.hdr.sgml : 20200207
20200207160854
ACCESSION NUMBER: 0001209191-20-007477
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20200207
DATE AS OF CHANGE: 20200207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20587467
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-05
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2020-02-05
4
A
0
12136
0.00
A
45376
D
Common Stock
2020-02-05
4
A
0
9800
0.00
A
55176
D
Common Stock
2020-02-05
4
A
0
12387
0.00
A
67563
D
Common Stock
2020-02-06
4
M
0
1564
187.53
A
69127
D
Common Stock
2020-02-06
4
M
0
1223
155.57
A
70350
D
Common Stock
2020-02-06
4
S
0
1511
238.71
D
68839
D
Common Stock
2020-02-06
4
S
0
725
239.47
D
68114
D
Common Stock
2020-02-06
4
S
0
230
240.53
D
67884
D
Common Stock
2020-02-06
4
S
0
150
241.08
D
67734
D
Common Stock
2020-02-06
4
S
0
171
242.47
D
67563
D
Common Stock
140
I
401(k)
Stock Option (Right to Buy)
187.53
2020-02-06
4
M
0
1564
0.00
D
2029-02-05
Common Stock
1564
18770
D
Stock Option (Right to Buy)
155.57
2020-02-06
4
M
0
1223
0.00
D
2028-02-05
Common Stock
1223
9783
D
Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020.
Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 02/24/2020.
Restricted stock unit award that vests in installments beginning on 02/10/2021.
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $238.71 (range $238.07 to $239.05).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $239.47 (range $239.11 to $240.04).
Open market sales reported on this line occurred at a weighted average price of $240.53 (range $240.40 to $240.60).
Open market sales reported on this line occurred at a weighted average price of $241.08 (range $241.04 to $241.12).
The option vests in 16 quarterly installments from 02/06/2019.
The option vests in 16 quarterly installments from 02/06/2018.
/s/ Omar White, Attorney-in-Fact
2020-02-07